5 and most preferably from about 0 075 0 25 mixtures of the surfactants are also contemplated it is thought that the surfactants provide a temporary reversible protecting system during the polymer conjugation process surfactants have been shown to be effective in selectively discouraging polymer aggregates while allowing lysine based or amino terminal based conjugation to proceed the present poly ethylene glycol modified hgh or agonist variant thereof has a more enduring pharmacological effect which may be possibly attributed to its prolonged half life in vivo furthermore the present poly ethylene glycol modified hgh or agonist variant thereof may be useful for the treatment of hypo pituitary dwarfism ghd adult growth hormone deficiency turner 39 s syndrome growth failure in children who were born short for gestational age sga prader willi syndrome pws chronic renal insufficiency cri aids wasting and aging the present poly ethylene glycol modified hgh or agonist variant thereof may be formulated into pharmaceuticals containing also a pharmaceutically acceptable diluent an agent for preparing an isotonic solution a ph conditioner and the like in order to administer them into a patient the above pharmaceuticals may be administered subcutaneously intramuscularly intravenously pulmonary intradermally or orally depending on a purpose of treatment a dose may be also based on the kind and condition of the disorder of a patient to be treated being normally between 0 1 mg and 5 mg by injection and between 0 1 mg and 50 mg in an oral administration for an adult the polymeric substances included are also preferably water soluble at.